15 September 2023
Malaysia's DCA has approved Apretude (cabotegravir) for high-risk groups after an Asean joint assessment, the first and only treatment by injection for HIV pre-exposure prevention. Cabotegravir only has to be taken every 2 months, unlike daily PrEP pills.